Utilizing key biomarkers such as low monocyte HLA-DR expression, persistent lymphocytopenia, and elevated PD-1/CTLA-4 for immune stratification is the core tool for selecting the correct timing and suitable patients. Here, CTLA4 is linked to lymphopenia.